title: High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial.
authors.affiliation: Department of Radiology, Oncology and Radiation Science, Uppsala University , Uppsala , Sweden.
authors.forename: Anna
authors.initials: A
authors.lastname: Laurell
authors.forename: Arne
authors.initials: A
authors.lastname: Kolstad
authors.forename: Mats
authors.initials: M
authors.lastname: Jerkeman
authors.forename: Riikka
authors.initials: R
authors.lastname: Räty
authors.forename: Christian H
authors.initials: CH
authors.lastname: Geisler
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000473:pathology*; D000069283:Rituximab; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D003561:Cytarabine; D000069283:Rituximab